Alimera Completes Recruitment for the Synchronicity Study
January 04, 2024 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis
June 29, 2023 08:02 ET
|
Alumis Inc
– Patient dosing initiated in LUMUS, a 388 patient Phase 2b clinical trial of ESK-001 for the treatment of SLE – – Patient dosing initiated in OPTYK-1, a proof-of-concept clinical trial of ESK-001...
Alimera Acquires U.S. Commercial Rights to YUTIQ®
May 18, 2023 07:00 ET
|
Alimera Sciences, Inc.
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland
September 20, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal
August 09, 2022 08:00 ET
|
Alimera Sciences, Inc.
Reimbursement granted with no restrictions to the labelAlimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global...
Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France
July 22, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
July 08, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Announces Launch of ILUVIEN® for Uveitis in Spain
February 07, 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands
December 09, 2020 08:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN® Into Nordic Countries
August 13, 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...